Mineralys Therapeutics, Inc. Common Stock Total Liabilities
Mineralys Therapeutics, Inc. Common Stock total liabilities. Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has total liabilities worth $116.94 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MLYS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Mineralys Therapeutics, Inc. Common Stock (2020–2025)
Total liabilities of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore Mineralys Therapeutics, Inc. Common Stoc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Mineralys Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SKYWORTH GRP UNSP.ADR/30
F:KYW0
|
Germany | €53.44 Billion |
|
Guangdong Ellington Electronics Technology Co Ltd
SHG:603328
|
China | CN¥2.33 Billion |
|
First Tractor Co Ltd
SHG:601038
|
China | CN¥6.66 Billion |
|
Cetc Potevio Science&Technology Co Ltd
SHE:002544
|
China | CN¥5.55 Billion |
|
Hankook Tire Worldwide
KO:000240
|
Korea | ₩452.41 Billion |
|
Dongfeng Automobile Co Ltd
SHG:600006
|
China | CN¥7.67 Billion |
|
Shenzhen Sinexcel Electric Co Ltd
SHE:300693
|
China | CN¥1.99 Billion |
|
Luolai Home Textile Co Ltd
SHE:002293
|
China | CN¥2.53 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Mineralys Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Mineralys Therapeutics, Inc. Common Stoc.
Liquidity & Leverage Metrics
Mineralys Therapeutics, Inc. Common Stock Total Liabilities Ratios Explained
Mineralys Therapeutics, Inc. Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 34.46 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mineralys Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $15.11 Million | +3.19% |
| 2024-12-31 | $14.65 Million | +39.73% |
| 2023-12-31 | $10.48 Million | -93.71% |
| 2022-12-31 | $166.71 Million | +389.61% |
| 2021-12-31 | $34.05 Million | +569.88% |
| 2020-12-31 | $5.08 Million | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more